Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xeljanz tofacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Xeljanz tofacitinib Cancelled
Xeljanz Tofacitinib Arthritis, rheumatoid List with criteria/condition Complete
Xeomin incobotulinumtoxinA Chronic sialorrhea associated with neurological disorders Reimburse with clinical criteria and/or conditions Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Blepharospasm List in a similar manner Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Cervical Dystonia List in a similar manner Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Spasticity, Post-stroke Do not list Complete
Xermelo telotristat carcinoid syndrome Do not reimburse Complete
XGEVA Denosumab Prevention of skeletal-related events due to bone metastases from solid tumours List with clinical criteria and/or conditions Complete
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from breast cancer List with clinical criteria and/or conditions Complete
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer List with clinical criteria and/or conditions Complete
Xiaflex Collagenase clostridium histolyticum Dupuytren’s contracture List with criteria/condition Complete
XigDuo dapagliflozin/metformin hydrochloride Diabetes Mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Xofluza baloxavir marboxil Influenza Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Xolair omalizumab Chronic rhinosinusitis with nasal polyps Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Xolair Omalizumab Asthma, severe persistent Cancelled
Xolair Omalizumab Asthma, severe persistent Do not list Complete
Xolair Omalizumab Chronic idiopathic urticaria List with clinical criteria and/or conditions Complete
Xolair Omalizumab (Drug Plan Submission) Asthma, severe persistent Reimburse with clinical criteria and/or conditions Complete
Xospata Gilteritinib Reimburse with clinical criteria and/or conditions Complete
Xpovio selinexor Multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide Non-metastatic castration-resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide mHSPC Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide First Line Metastatic Castration-Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete